To Evaluate Different Conditioning Regimens for HLA Matched Donor Transplantation in Severe Aplastic Anemia: a Prospective, Multicenter, Randomized Controlled Study

Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 4
SUMMARY

Hematopoietic stem cell transplantation (HSCT) from a human leukocyte antigen (HLA) -matched donor is an effective option for severe aplastic anemia (SAA), but there is no standardized and recommended conditioning regimen. The occurrence of mixed chimerism after transplantation is associated with secondary graft failure and poor failure-free survival. Previous studies have shown that Fludarabine (Flu)/ Cyclophosphamide (Cy)/ antithymocyte globulin (antithymocyte globulin), ATG) and Cy/ATG conditioning regimens had higher rates of mixed chimerism and poorer failure-free survival. A small cohort study has suggested that adding busulfan to Flu/Cy/ATG or Cy/ATG can reduce the incidence of mixed chimerism and improve failure-free survival. This study was a prospective, multicenter, randomized controlled trial to compare the efficacy and safety of different conditioning regimens in the treatment of severe aplastic anemia (SAA) after hematopoietic stem cell transplantation (HSCT) from HLA-identical sibling or unrelated donor.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 1
Maximum Age: 50
Healthy Volunteers: f
View:

• Diagnosed as SAA/vSAA

• Indication for hematopoietic stem cell transplantation

• Available HLA matched sibling or unrelated donor

• No active infection

• No serious organ damage: liver and kidney function (ALT and AST \< 2.5 times normal value, normal renal function, no cardiac insufficiency)

• Signed informed consent

• High risk factors of mixed chimerism, at least one of the following

‣ Age \< 18 years old

⁃ Ferritin level ≥2500ng/ml before transplantation

Locations
Other Locations
China
Deparment of Hematology, Peking University People's Hospital
RECRUITING
Beijing
Contact Information
Primary
Zheng-Li Xu, M.D.
xuzhengli0202@163.com
+8613501338951
Time Frame
Start Date: 2023-11-15
Estimated Completion Date: 2025-12-31
Participants
Target number of participants: 160
Treatments
Experimental: Busulfan included group
The conditioning regimens were Bu/Flu/Cy/ATG or Bu/Cy/ATG, depending on the patient's risk factors of regimen related cardiotoxicity.
Other: Control group
The conditioning regimens were Flu/Cy/ATG or Cy/ATG, depending on the patient's risk factors of regimen related cardiotoxicity.
Related Therapeutic Areas
Sponsors
Leads: Peking University People's Hospital

This content was sourced from clinicaltrials.gov

Similar Clinical Trials